https://www.nice.org.uk/guidance/ta875; accessed on 5/10/2023

Wilding JPH, Batterham RL, Calanna S, et al.; the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183

Davies M, Færch L, Jeppesen OK, et al.; the STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-84. https://doi.org/10.1016/S0140-6736(21)00213-0

Wadden TA, Bailey TS, Billings LK, et al.; the STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. https://doi.org/10.1001/jama.2021.1831

Rubino D, Abrahamsson N, Davies M, et al.; the STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1–12. https://doi.org/10.1001/jama.2021.3224

Garvey WT, Batterham RL, Bhatta M, et al.; the STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28(10):2083-91. https://doi.org/10.1038/s41591-022-02026-4

Kadowaki T, Isendahl J, Khalid U, et al.; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2022;10(3):193-206. https://doi.org/10.1016/S2213-8587(22)00008-0.

Rubino DM, Greenway FL, Khalid U, et al.; the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. The STEP 8 Randomized Clinical Trial. JAMA 2022;327(2):138-150. https://doi.org/10.1001/jama.2021.23619.

https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019/health-survey-for-england-2019-data-tables; accessed 05/10/2023.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. https://doi.org/10.1056/NEJMoa2307563.

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; the STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389(12):1069-84. https://doi.org/10.1056/NEJMoa2306963.

Wilding JPH, Batterham RL, Davies M, et al.; the STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. https://doi.org/10.1111/dom.14725.

https://www.nice.org.uk/guidance/TA924; accessed on 07/06/2024